A pharmaceutical manufacturer was preparing to launch 2 biosimilars with autoimmune disease indications across 6 European markets. With several access challenges for both products anticipated, this case study shares our approach to the assessment of likely access conditions and price potentials at launch, as well as the evidence generation needed to improve those scenarios across markets. The findings were critical to informing the development of a pricing strategy for both biosimilars.